Zenas BioPharma, Inc. Common Stock
Buy, Hold or Sell?
Let's analyze Zenas BioPharma, Inc. Common Stock together
I guess you are interested in Zenas BioPharma, Inc. Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of Zenas BioPharma, Inc. Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
Get notifications about Zenas BioPharma, Inc. Common Stock
I send you an email if I find something interesting about Zenas BioPharma, Inc. Common Stock.
1. Quick Overview
1.1. Quick analysis of Zenas BioPharma, Inc. Common Stock (30 sec.)
1.2. What can you expect buying and holding a share of Zenas BioPharma, Inc. Common Stock? (30 sec.)
How much money do you get?
What is your share worth?
+ What do you gain per year?
2. Detailed Analysis
2.1. Valuation of Zenas BioPharma, Inc. Common Stock (5 min.)
2.2. Growth of Zenas BioPharma, Inc. Common Stock (5 min.)
Is Zenas BioPharma, Inc. Common Stock growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | -$288.7m | ? | ? | ? |
How much money is Zenas BioPharma, Inc. Common Stock making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | -$13.6m | ? | ? | ? |
Net Profit Margin | 17.8% | ? | - | - |
How much money comes from the company's main activities?
2.3. Financial Health of Zenas BioPharma, Inc. Common Stock (5 min.)
2.4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
3. Summary and Key Metrics
3.1. What can you expect buying and holding a share of Zenas BioPharma, Inc. Common Stock?
Welcome investor! Zenas BioPharma, Inc. Common Stock's management wants to use your money to grow the business. In return you get a share of Zenas BioPharma, Inc. Common Stock.
First you should know what it really means to hold a share of Zenas BioPharma, Inc. Common Stock. And how you can make/lose money.
Speculation
The Price per Share of Zenas BioPharma, Inc. Common Stock is $. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.
If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:
- The fundamentals: the financial health trends of Zenas BioPharma, Inc. Common Stock.
- The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
- The book value: what is the market price compared to it's book value.
Investing
If you really want to invest in Zenas BioPharma, Inc. Common Stock, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:
- You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-7.26. Based on the TTM, the Book Value Change Per Share is $-1.81 per quarter.
- You may receive quarterly/yearly dividend in the form of additional shares.
- You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
How much money are you going to get?
MRQ | TTM | YOY | 5Y | 10Y | ||||||
---|---|---|---|---|---|---|---|---|---|---|
$ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | |
Usd Eps | -0.95 | -0.34 | -0.34 | -0.34 | ||||||
Usd Book Value Change Per Share | -0.91 | -1.81 | -1.81 | -1.81 | ||||||
Usd Dividend Per Share | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
Usd Total Gains Per Share | -0.91 | -1.81 | -1.81 | -1.81 | ||||||
Usd Price Per Share | 0.00 | - | 0.00 | - | 0.00 | - | 0.00 | - | ||
Price to Earnings Ratio | 0.00 | - | 0.00 | - | 0.00 | - | 0.00 | - | ||
Price-to-Total Gains Ratio | ||||||||||
Price to Book Ratio | 0.00 | - | 0.00 | - | 0.00 | - | 0.00 | - | ||
Price-to-Total Gains Ratio |
When do you get the money?
How sure are you?
Based on the past periods, how sure are you to get value out of your investment.
Linear %
Trailing 12 Months | 3Y | 5 Year | 10 Year | ALLTIME | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | % | % | % | % | ||||||||||||||||
Earnings Per Share | 1.0 | 3.0 | 0.0 | 25.0% | 1.0 | 3.0 | 0.0 | 25.0% | 1.0 | 3.0 | 0.0 | 25.0% | 1.0 | 3.0 | 0.0 | 25.0% | 1.0 | 3.0 | 0.0 | 25.0% |
Book Value Change Per Share | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 4.0 | 0.0 | 0.0% |
Dividend per Share | 0.0 | 0.0 | 4.0 | 0.0% | 0.0 | 0.0 | 4.0 | 0.0% | 0.0 | 0.0 | 4.0 | 0.0% | 0.0 | 0.0 | 4.0 | 0.0% | 0.0 | 0.0 | 4.0 | 0.0% |
Total Gains per Share | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 4.0 | 0.0 | 0.0% |
3.2. Key Performance Indicators
The key performance indicators of Zenas BioPharma, Inc. Common Stock compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | -0.912 | -1.814 | +99% | - | - | -1.814 | +99% | -1.814 | +99% |
Book Value Per Share | - | - | -7.257 | -6.089 | -16% | - | - | -6.089 | -16% | -6.089 | -16% |
Current Ratio | - | - | 4.823 | 3.408 | +42% | - | - | 3.408 | +42% | 3.408 | +42% |
Debt To Asset Ratio | - | - | 2.444 | 4.079 | -40% | - | - | 4.079 | -40% | 4.079 | -40% |
Debt To Equity Ratio | - | - | - | - | 0% | - | - | - | 0% | - | 0% |
Dividend Per Share | - | - | - | - | 0% | - | - | - | 0% | - | 0% |
Eps | - | - | -0.954 | -0.344 | -64% | - | - | -0.344 | -64% | -0.344 | -64% |
Free Cash Flow Per Share | - | - | -0.779 | -0.212 | -73% | - | - | -0.212 | -73% | -0.212 | -73% |
Free Cash Flow To Equity Per Share | - | - | 3.688 | 1.027 | +259% | - | - | 1.027 | +259% | 1.027 | +259% |
Gross Profit Margin | - | - | 1.000 | 1.000 | 0% | - | - | 1.000 | 0% | 1.000 | 0% |
Market Cap | - | 0% | - | - | 0% | - | - | - | 0% | - | 0% |
Net Profit Margin | - | - | - | 0.178 | -100% | - | - | 0.178 | -100% | 0.178 | -100% |
Operating Margin | - | - | - | - | 0% | - | - | - | 0% | - | 0% |
Operating Ratio | - | - | - | 0.072 | -100% | - | - | 0.072 | -100% | 0.072 | -100% |
Pb Ratio | - | 0% | - | - | 0% | - | - | - | 0% | - | 0% |
Pe Ratio | - | 0% | - | - | 0% | - | - | - | 0% | - | 0% |
Price Per Share | - | 0% | - | - | 0% | - | - | - | 0% | - | 0% |
Price To Free Cash Flow Ratio | - | 0% | - | - | 0% | - | - | - | 0% | - | 0% |
Quick Ratio | - | - | - | - | 0% | - | - | - | 0% | - | 0% |
Return On Assets | - | - | -0.190 | -0.173 | -9% | - | - | -0.173 | -9% | -0.173 | -9% |
Return On Equity | - | - | - | - | 0% | - | - | - | 0% | - | 0% |
Total Gains Per Share | - | - | -0.912 | -1.814 | +99% | - | - | -1.814 | +99% | -1.814 | +99% |
Usd Book Value | - | - | -288782000.000 | -242307500.000 | -16% | - | - | -242307500.000 | -16% | -242307500.000 | -16% |
Usd Book Value Change Per Share | - | - | -0.912 | -1.814 | +99% | - | - | -1.814 | +99% | -1.814 | +99% |
Usd Book Value Per Share | - | - | -7.257 | -6.089 | -16% | - | - | -6.089 | -16% | -6.089 | -16% |
Usd Dividend Per Share | - | - | - | - | 0% | - | - | - | 0% | - | 0% |
Usd Eps | - | - | -0.954 | -0.344 | -64% | - | - | -0.344 | -64% | -0.344 | -64% |
Usd Free Cash Flow | - | - | -30994000.000 | -8422250.000 | -73% | - | - | -8422250.000 | -73% | -8422250.000 | -73% |
Usd Free Cash Flow Per Share | - | - | -0.779 | -0.212 | -73% | - | - | -0.212 | -73% | -0.212 | -73% |
Usd Free Cash Flow To Equity Per Share | - | - | 3.688 | 1.027 | +259% | - | - | 1.027 | +259% | 1.027 | +259% |
Usd Market Cap | - | 0% | - | - | 0% | - | - | - | 0% | - | 0% |
Usd Price Per Share | - | 0% | - | - | 0% | - | - | - | 0% | - | 0% |
Usd Profit | - | - | -37977000.000 | -13689250.000 | -64% | - | - | -13689250.000 | -64% | -13689250.000 | -64% |
Usd Revenue | - | - | - | 12500000.000 | -100% | - | - | 12500000.000 | -100% | 12500000.000 | -100% |
Usd Total Gains Per Share | - | - | -0.912 | -1.814 | +99% | - | - | -1.814 | +99% | -1.814 | +99% |
EOD | +0 -0 | MRQ | TTM | +9 -12 | YOY | +0 -0 | 5Y | +9 -12 | 10Y | +9 -12 |
3.3 Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | 0.000 | |
Price to Book Ratio (EOD) | Between | 0-1 | 0.000 | |
Net Profit Margin (MRQ) | Greater than | 0 | 0.000 | |
Operating Margin (MRQ) | Greater than | 0 | 0.000 | |
Quick Ratio (MRQ) | Greater than | 1 | 0.000 | |
Current Ratio (MRQ) | Greater than | 1 | 4.823 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 2.444 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 0.000 | |
Return on Equity (MRQ) | Greater than | 0.15 | 0.000 | |
Return on Assets (MRQ) | Greater than | 0.05 | -0.190 | |
Total | 4/10 (40.0%) |
3.4 Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Total | 0/0 (0.0%) |
4. In-depth Analysis
4.1 About Zenas BioPharma, Inc. Common Stock
- https://zenasbio.com
- Biotechnology
- 114
- North Building, Waltham, MA, United States, 02451
Google Maps Bing Maps
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Fundamental data was last updated by Penke on 2024-11-15 09:41:05.
4.2 In-depth Summary
4.2.1. Financial Health Summary
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge profit. | ||
Using its assets, the company is very inefficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very efficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its short-term debts. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is unable to pay all its debts by selling its assets. |
4.2.2. Valuation Summary
Compared to previous year | Compared to industry |
---|
4.3 Financial Health
4.3.1. Profitability
4.3.1 Profitability
4.3.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
- A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of Zenas BioPharma, Inc. Common Stock:
- The MRQ is 0.0%. The data is not here.
Trends
- The 5Y is 17.8%. Compared to the TTM, the 5Y term is not trending.
- The 10Y is 17.8%. Compared to the 5Y term, the 10Y term is not trending.
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -120.2%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -210.7%. trending up. +2
4.3.1.2. Return on Assets
- Above 5% is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
- -19.0% Return on Assets means that Zenas BioPharma, Inc. Common Stock generated $-0.19 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of Zenas BioPharma, Inc. Common Stock:
Trends
- The 5Y is -17.3%. Compared to the TTM, the 5Y term is not trending.
- The 10Y is -17.3%. Compared to the 5Y term, the 10Y term is not trending.
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -11.0%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -11.8%. trending down. -2
4.3.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
- 0.0% Return on Equity means Zenas BioPharma, Inc. Common Stock generated $0.00 for each $1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of Zenas BioPharma, Inc. Common Stock:
- The MRQ is 0.0%. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -14.1%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -15.8%. trending up. +2
4.3.2. Operating Efficiency of Zenas BioPharma, Inc. Common Stock.
4.3.2. Operating Efficiency
4.3.2.1. Operating Margin
- Measures how much profit Zenas BioPharma, Inc. Common Stock makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
- An Operating Margin of 0.0% means the company generated $0.00 for each $1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of Zenas BioPharma, Inc. Common Stock:
- The MRQ is 0.0%. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -267.8%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -313.4%. trending up. +2
4.3.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.
Let's take a look of the Operating Ratio trends of Zenas BioPharma, Inc. Common Stock:
- The MRQ is 0.000. The data is not here.
Trends
- The 5Y is 0.072. Compared to the TTM, the 5Y term is not trending.
- The 10Y is 0.072. Compared to the 5Y term, the 10Y term is not trending.
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.631. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 3.412. trending down. +2
4.4.3. Liquidity of Zenas BioPharma, Inc. Common Stock.
4.4.3. Liquidity
4.4.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 4.82 means the company has $4.82 in assets for each $1 in short-term debts.
Let's take a look of the Current Ratio trends of Zenas BioPharma, Inc. Common Stock:
Trends
- The 5Y is 3.408. Compared to the TTM, the 5Y term is not trending.
- The 10Y is 3.408. Compared to the 5Y term, the 10Y term is not trending.
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.690. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 3.875. trending down. -2
4.4.3.2. Quick Ratio
- Above 1 is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
- A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of Zenas BioPharma, Inc. Common Stock:
- The MRQ is 0.000. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.122. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 3.451. trending down. -2
4.5.4. Solvency of Zenas BioPharma, Inc. Common Stock.
4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to Biotechnology industry mean.
- A Debt to Asset Ratio of 2.44 means that Zenas BioPharma, Inc. Common Stock assets are financed with 244.4% credit (debt) and the remaining percentage (100% - 244.4%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of Zenas BioPharma, Inc. Common Stock:
Trends
- The 5Y is 4.079. Compared to the TTM, the 5Y term is not trending.
- The 10Y is 4.079. Compared to the 5Y term, the 10Y term is not trending.
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.353. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.350. trending up. -2
4.5.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
- A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of Zenas BioPharma, Inc. Common Stock:
- The MRQ is 0.000. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.393. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.435. trending down. +2
4.6. Market Valuation
4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare Zenas BioPharma, Inc. Common Stock to the Biotechnology industry mean.
- A PE ratio of 0.00 means the investor is paying $0.00 for every $1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of Zenas BioPharma, Inc. Common Stock:
- The MRQ is 0.000. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -2.454. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -3.147. trending up. +2
4.6.2.2. Price To Free Cash Flow Ratio
Let's take a look of the Price To Free Cash Flow Ratio trends of Zenas BioPharma, Inc. Common Stock:
- The MRQ is 0.000. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's priceToFreeCashFlowRatio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -3.363. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -3.667. trending up. +2
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of 0.00 means the investor is paying $0.00 for each $1 in book value.
Let's take a look of the Price to Book Ratio trends of Zenas BioPharma, Inc. Common Stock:
- The MRQ is 0.000. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.028. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 2.339. trending down. +2
4.6.2. Total Gains per Share
6. Financial Statements
6.1. Latest Balance Sheet
Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 488,734 |
Total Stockholder Equity | + -288,782 |
Total Assets | = 199,952 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 706 |
Long-term Assets Other | 185 |
Long-term Assets (as reported) | 11,352 |
---|---|
Long-term Assets (calculated) | 891 |
+/- | 10,461 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt | 508 |
Long-term Liabilities (as reported) | 449,626 |
---|---|
Long-term Liabilities (calculated) | 508 |
+/- | 449,118 |
Total Stockholder Equity
Retained Earnings | -296,180 |
Total Stockholder Equity (as reported) | -288,782 |
---|---|
Total Stockholder Equity (calculated) | -296,180 |
+/- | 7,398 |
Other
Capital Stock | 1 |
Net Invested Capital | -288,782 |
Net Working Capital | 149,492 |
Property Plant and Equipment Gross | 706 |
6.2. Balance Sheets Structured
Currency in USD. All numbers in thousands.
Trend | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 199,952 | 49,051 | 68,180 | 83,792 | 74,579 | |||||
> Total Current Assets |
| 188,600 | 39,705 | 59,804 | 76,676 | 68,444 | |||||
Cash And Cash Equivalents |
| 183,930 | 37,154 | 56,857 | 72,311 | 67,209 | |||||
Other Current Assets |
| 4,670 | 2,551 | 2,947 | 4,365 | 1,235 | |||||
> Long-term Assets |
| 11,352 | 9,346 | 8,376 | 7,116 | 6,135 | |||||
Property Plant Equipment |
| 706 | 847 | 1,014 | 1,147 | 1,801 | |||||
Long-term Assets Other |
| 185 | 184 | 186 | 5,969 | 212 | |||||
> Total Liabilities |
| 488,734 | 301,546 | 293,901 | 286,024 | 266,865 | |||||
> Total Current Liabilities |
| 39,108 | 30,333 | 23,258 | 15,557 | 25,967 | |||||
Accounts payable |
| 8,358 | 8,830 | 5,396 | 2,276 | 5,815 | |||||
Other Current Liabilities |
| 530 | 1,500 | 0 | 0 | 0 | |||||
> Long-term Liabilities |
| 449,626 | 271,213 | 270,643 | 270,467 | 240,898 | |||||
Capital Lease Obligations Min Short Term Debt |
| 508 | 649 | 813 | 964 | 1,527 | |||||
> Total Stockholder Equity |
| -288,782 | -252,495 | -225,721 | -202,232 | -192,286 | |||||
Common Stock | 0 | 0 | 0 | 0 | 0 | ||||||
Retained Earnings | -296,180 | -258,203 | -230,403 | -205,816 | -193,279 | ||||||
Capital Surplus | 0 | 0 | 0 | 0 | 0 | ||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | ||||||
Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
6.3. Balance Sheets
Currency in USD. All numbers in thousands.
6.4. Cash Flows
Currency in USD. All numbers in thousands.
6.5. Income Statements
Currency in USD. All numbers in thousands.
6.6. Latest Income Statement
Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.
Gross Profit (+$) | ||
---|---|---|
totalRevenue | 50,000 | |
Cost of Revenue | -0 | |
Gross Profit | 0 | 50,000 |
Operating Income (+$) | ||
Gross Profit | 0 | |
Operating Expense | -77,147 | |
Operating Income | -27,147 | -77,147 |
Operating Expense (+$) | ||
Research Development | 60,033 | |
Selling General Administrative | 17,114 | |
Selling And Marketing Expenses | 0 | |
Operating Expense | 77,147 | 77,147 |
Net Interest Income (+$) | ||
Interest Income | 0 | |
Interest Expense | -0 | |
Other Finance Cost | -0 | |
Net Interest Income | 0 | |
Pretax Income (+$) | ||
Operating Income | -27,147 | |
Net Interest Income | 0 | |
Other Non-Operating Income Expenses | 0 | |
Income Before Tax (EBT) | -36,823 | -17,471 EBIT - interestExpense = 0 -37,124 -37,124 |
Interest Expense | 0 | |
Earnings Before Interest and Taxes (EBIT) | 0 | -36,823 |
Earnings Before Interest and Taxes (EBITDA) | 0 | |
After tax Income (+$) | ||
Income Before Tax | -36,823 | |
Tax Provision | -301 | |
Net Income From Continuing Ops | -37,124 | -37,124 |
Net Income | -37,124 | |
Net Income Applicable To Common Shares | 0 | |
Non-recurring Events | ||
Discontinued Operations | 0 | |
Extraordinary Items | 0 | |
Effect of Accounting Charges | 0 | |
Other Items | 0 | |
Non Recurring | 0 | |
Other Operating Expenses | 0 | |
Total Other Income/Expenses Net | -9,676 | 0 |
1.4. Technical Score
Let's check the technical score of Zenas BioPharma, Inc. Common Stock based on Penke's default Symbol scanner.
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Total | 0/0 (0.0%) |
Get notifications about Zenas BioPharma, Inc. Common Stock
I send you an email if I find something interesting about Zenas BioPharma, Inc. Common Stock.
Comments
How you think about this?